Opinion

Video

BOND-003 Trial and Cretostimogene for Treatment of NMIBC

Author(s):

Mark D. Tyson, MD, MPH,Gary D. Steinberg, MD

Panelists discuss how cretostimogene grenadenorepvec is an intravesical oncolytic virus therapy targeting BCG-unresponsive bladder cancer through selective replication in tumor cells and immune stimulation via granulocyte-macrophage colony-stimulating factor expression.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • What is cretostimogene grenadenorepvec? Please describe its mechanism of action.
      • Discuss the phase 3 BOND-003 clinical trial investigating the use of the intravesical immunotherapy cretostimogene grenadenorepvec in patients with high-risk, BCG-unresponsive disease that was recently presented at the Society of Urologic Oncology 2024.
      • What are your impressions of the BOND-003 data?

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      1 expert is featured in this series.
      Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response
      Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
      Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
      Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
      Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
      1 expert is featured in this series.
      Approaching Corticosteroid Selection With Abiraterone in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
      1 expert is featured in this series.
      Incorporating Micronized Abiraterone and Low-Fat Meal Dosing: Monitoring Efficacy and Tolerability
      DNA helix | Image Credit: © Radomir Jovanovic - stock.adobe.com
      Betty Wang, MD, and Laura Bukavina, MD, MPH, MSc, discuss ctDNA's role in NMIBC treatment decisions
      The Growing Call for Combination Therapy in NMIBC Treatment
      The Growing Call for Combination Therapy in NMIBC Treatment
      Optimizing NMIBC Treatment Through Sequencing and Patient Preference
      Optimizing NMIBC Treatment Through Sequencing and Patient Preference
      Medical stethoscope and dollar bills | Image Credit: © Kuzmick - stock.adobe.com
      TMT for bladder cancer: Balancing cost and quality of life
      Anne Schuckman, MD, outlines current challenges in NMIBC care
      Anne Schuckman, MD, outlines current challenges in NMIBC care
      Related Content
      Mitomycin intravesical solution demonstrates long-term durability in LG-IR-NMIBC
      July 21st 2025

      Mitomycin intravesical solution demonstrates long-term durability in LG-IR-NMIBC

      Hannah Clarke
      Mitomycin intravesical solution was granted FDA approval in June 2025 for recurrent LG-IR-NMIBC.
      Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD
      July 15th 2025

      Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

      Amy M. Pearlman, MD
      Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.
      FDA grants priority review to NDA for TAR-200 in BCG-unresponsive NMIBC
      July 17th 2025

      FDA grants priority review to NDA for TAR-200 in BCG-unresponsive NMIBC

      Hannah Clarke
      The new drug application for TAR-200 is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.
      Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
      June 30th 2025

      Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

      Amy M. Pearlman, MD
      Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
      Meeting with FDA paves way for phase 3 trial of Alpha1H in NMIBC
      July 16th 2025

      Meeting with FDA paves way for phase 3 trial of Alpha1H in NMIBC

      Hannah Clarke
      Alpha1H was granted a fast track designation in November 2023.
      Data support combination intravesical chemotherapy for high-risk NMIBC
      July 10th 2025

      Data support combination intravesical chemotherapy for high-risk NMIBC

      Hannah Clarke
      “This study adds to the growing body of evidence supporting combination intravesical chemotherapy as a feasible option even after prior treatment failure," says Ian M. McElree, MD.
      © 2025 MJH Life Sciences

      All rights reserved.